BRPI0517285A - nitrobenzindóis e seu emprego na terapia de cáncer - Google Patents

nitrobenzindóis e seu emprego na terapia de cáncer

Info

Publication number
BRPI0517285A
BRPI0517285A BRPI0517285-3A BRPI0517285A BRPI0517285A BR PI0517285 A BRPI0517285 A BR PI0517285A BR PI0517285 A BRPI0517285 A BR PI0517285A BR PI0517285 A BRPI0517285 A BR PI0517285A
Authority
BR
Brazil
Prior art keywords
cancer therapy
nitrobenzindoles
drugs
nitrobenzinds
radiosensitizers
Prior art date
Application number
BRPI0517285-3A
Other languages
English (en)
Portuguese (pt)
Inventor
William Alexander Denny
William Robert Wilson
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Shangjin Yang
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of BRPI0517285A publication Critical patent/BRPI0517285A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BRPI0517285-3A 2004-10-22 2005-10-21 nitrobenzindóis e seu emprego na terapia de cáncer BRPI0517285A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (1)

Publication Number Publication Date
BRPI0517285A true BRPI0517285A (pt) 2008-10-07

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517285-3A BRPI0517285A (pt) 2004-10-22 2005-10-21 nitrobenzindóis e seu emprego na terapia de cáncer

Country Status (14)

Country Link
US (1) US7718688B2 (enExample)
EP (1) EP1809603A4 (enExample)
JP (1) JP2008517905A (enExample)
KR (1) KR20070083806A (enExample)
CN (1) CN101044114B (enExample)
AU (1) AU2005296389B2 (enExample)
BR (1) BRPI0517285A (enExample)
CA (1) CA2584702A1 (enExample)
IL (1) IL182652A0 (enExample)
MX (1) MX2007004596A (enExample)
NZ (1) NZ536107A (enExample)
RU (1) RU2007118938A (enExample)
WO (1) WO2006043839A1 (enExample)
ZA (1) ZA200703699B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
AU2008289485B2 (en) 2007-08-21 2014-08-14 Senomyx, Inc. Human T2R bitterness receptors and uses thereof
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
NO2344478T3 (enExample) * 2008-11-03 2018-02-24
MX374267B (es) 2010-04-21 2025-03-06 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
SG10201911860VA (en) 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity
KR20160099725A (ko) 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
MX373458B (es) 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310725T1 (de) * 1996-09-12 2005-12-15 Auckland Uniservices Ltd Kondensierte n-acylindole als antitumormittel
US7192977B2 (en) * 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
AU2003228173A1 (en) * 2002-05-17 2003-12-02 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-(ring fused indol-5-yl(amine-derived)) compounds and analogues thereof, and to products obtained therefrom
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Also Published As

Publication number Publication date
CN101044114B (zh) 2012-02-15
CA2584702A1 (en) 2006-04-27
AU2005296389A1 (en) 2006-04-27
US7718688B2 (en) 2010-05-18
NZ536107A (en) 2007-06-29
RU2007118938A (ru) 2008-11-27
EP1809603A1 (en) 2007-07-25
US20080119442A1 (en) 2008-05-22
KR20070083806A (ko) 2007-08-24
CN101044114A (zh) 2007-09-26
AU2005296389B2 (en) 2012-03-15
WO2006043839A1 (en) 2006-04-27
MX2007004596A (es) 2007-06-22
JP2008517905A (ja) 2008-05-29
EP1809603A4 (en) 2009-09-02
IL182652A0 (en) 2007-07-24
ZA200703699B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
BRPI0517285A (pt) nitrobenzindóis e seu emprego na terapia de cáncer
Brodbelt et al. Glioblastoma in england: 2007–2011
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
BRPI0911442A2 (pt) conjugados potentes e ligantes hidrofílicos
BRPI0509201A (pt) agentes de acoplamento de receptor e usos terapêuticos destes
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
MY145089A (en) Pharmaceutical composition
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
BR112013032766A2 (pt) "compostos de ligação com catepsina, composto que visa catepsina, processo para a preparação dos referidos compostos e usos dos mesmos na preparação de medicamentos
IL198976A0 (en) Companion diagnostic assays for cancer therapy
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
BR112014018450A8 (pt) Fenilimidazopirazoles substituídos e sua utilização
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]